The global Acute Respiratory Distress Syndrome (ARDS) treatment market is expected to reach USD 9,954,720.47 thousand by 2030, from USD 4,577,440.16 thousand in 2022, growing at the CAGR of 10.6% in the forecast period of 2023 to 2030.
Market Segmentation
Global Acute Respiratory Distress Syndrome (Ards) Treatment Market, By Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause ( Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country ( U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Turkey, Hungary, Netherlands, Switzerland, Austria Lithuania, Poland, Russia, Ireland, Norway, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Israel, Egypt, Kuwait, Rest of Middle East and Africa, Brazil, Argentina, Peru, Rest of South America - Industry Trends and Forecast to 2030.
Overview of Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics
- Driver
- Increasing prevalence and incidence of acute lung injury in the market
- Restraint
- High cost of device and treatment
- Opportunity
- Strategic initiatives joined with new product launches by market players
Market Players
Some of the major market players operating in the global Acute Respiratory Distress Syndrome (ARDS) treatment market are listed below:
- Gilead Sciences, Inc.
- Terumo Medical Corporation
- Getinge
- LivaNova PLC
- Medtronic
- ResMed
- Fisher & Paykel Healthcare Limited.
- Dragerwerk AG & Co. KGaA
- NIPRO
- Fresenius SE & Co. KGaA
- Hamilton Medical
- Pfizer Inc.
- WEINMANN Emergency Medical Technology GmbH + Co. KG
- EUROSETS
- Armstrong Medical
- nice Neotech Medical Systems Pvt. Ltd.
- Besmed Health Business Corp.
TABLE OF CONTENTS
1 INTRODUCTION 41
- 1.1 OBJECTIVES OF THE STUDY 41
- 1.2 MARKET DEFINITION 41
- 1.3 OVERVIEW OF GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 41
- 1.4 LIMITATIONS 43
- 1.5 MARKETS COVERED 43
2 MARKET SEGMENTATION 45
- 2.1 MARKETS COVERED 45
- 2.2 GEOGRAPHICAL SCOPE 46
- 2.3 YEARS CONSIDERED FOR THE STUDY 47
- 2.4 CURRENCY AND PRICING 47
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 48
- 2.6 MULTIVARIATE MODELLING 51
- 2.7 TYPE LIFELINE CURVE 51
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 52
- 2.9 DBMR MARKET POSITION GRID 53
- 2.10 MARKET END USER COVERAGE GRID 54
- 2.11 VENDOR SHARE ANALYSIS 55
- 2.12 SECONDARY SOURCES 56
- 2.13 ASSUMPTIONS 56
3 EXECUTIVE SUMMARY 57
4 PREMIUM INSIGHTS 60
- 4.1 PESTEL ANALYSIS 61
- 4.2 PORTER'S FIVE FORCES 62
- 4.3 INSURANCE REIMBURSEMENT 63
- 4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 63
- 4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 63
- 4.3.3 ABBOTT CODING GUIDE FOR ECMO 64
- 4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 64
- 4.3.5 CERN HEALTH INSURANCE SCHEME 65
- 4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 65
- 4.3.7 AMERICAN HOSPITAL ASSOCIATION 66
- 4.4 PIPELINE ANALYSIS 67
- 4.5 PRICING ANALYSIS 69
5 MARKET OVERVIEW 70
- 5.1 DRIVERS 72
- 5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 72
- 5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 72
- 5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 73
- 5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 73
- 5.2 RESTRAINTS 74
- 5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 74
- 5.2.2 HIGH COST OF DEVICES AND TREATMENT 74
- 5.3 OPPORTUNITIES 75
- 5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 75
- 5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 75
- 5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 76
- 5.4 CHALLENGES 77
- 5.4.1 STRINGENT RULES & REGULATIONS 77
- 5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 78
6 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 79
- 6.1 OVERVIEW 80
- 6.2 MECHANICAL VENTILATION 83
- 6.2.1 HIGH-FLOW NASAL O2 84
- 6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 84
- 6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 84
- 6.2.4 PRONE POSITION VENTILATION 84
- 6.2.5 OTHERS 85
- 6.3 CORTICOSTEROIDS 85
- 6.3.1 METHYLPREDNISOLONE 86
- 6.3.2 DEXAMETHASONE 86
- 6.3.3 OTHERS 86
- 6.4 ANTIVIRAL MEDICATION 87
- 6.4.1 RIBAVIRIN 88
- 6.4.2 OSELTAMIVIR 88
- 6.4.3 OTHERS 88
- 6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 88
- 6.6 TOCILIZUMAB 89
- 6.7 OTHERS 89
7 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 90
- 7.1 OVERVIEW 91
- 7.2 SEPSIS 94
- 7.3 INHALATION OF HARMFUL SUBSTANCES 94
- 7.4 SEVERE PNEUMONIA 95
- 7.5 OTHERS 95
8 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 96
- 8.1 OVERVIEW 97
- 8.2 PARENTERAL 100
- 8.2.1 INTRAVENOUS 100
- 8.2.2 INTRAMUSCULAR 100
- 8.3 ORAL 101
- 8.4 OTHERS 101
9 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 102
- 9.1 OVERVIEW 103
- 9.2 HOSPITALS 106
- 9.3 SPECIALTY CLINICS 106
- 9.4 HOME HEALTHCARE 107
- 9.5 OTHERS 107
10 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 108
- 10.1 OVERVIEW 109
- 10.2 DIRECT TENDER 112
- 10.3 HOSPITAL PHARMACY 112
- 10.4 RETAIL PHARMACY 113
- 10.5 ONLINE PHARMACY 113
11 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 114
- 11.1 OVERVIEW 115
- 11.2 NORTH AMERICA 118
- 11.2.1 U.S. 123
- 11.2.2 CANADA 128
- 11.2.3 MEXICO 133
- 11.3 EUROPE 138
- 11.3.1 GERMANY 143
- 11.3.2 FRANCE 148
- 11.3.3 U.K. 153
- 11.3.4 ITALY 158
- 11.3.5 SPAIN 163
- 11.3.6 TURKEY 168
- 11.3.7 NETHERLANDS 173
- 11.3.8 SWITZERLAND 178
- 11.3.9 BELGIUM 183
- 11.3.10 RUSSIA 188
- 11.3.11 REST OF EUROPE 193
- 11.4 ASIA-PACIFIC 194
- 11.4.1 JAPAN 200
- 11.4.2 CHINA 205
- 11.4.3 INDIA 210
- 11.4.4 SOUTH KOREA 215
- 11.4.5 AUSTRALIA 220
- 11.4.6 SINGAPORE 225
- 11.4.7 THAILAND 230
- 11.4.8 MALAYSIA 235
- 11.4.9 INDONESIA 240
- 11.4.10 PHILIPPINES 245
- 11.4.11 REST OF ASIA-PACIFIC 250
- 11.5 SOUTH AMERICA 251
- 11.5.1 BRAZIL 256
- 11.5.2 ARGENTINA 261
- 11.5.3 REST OF SOUTH AMERICA 266
- 11.6 MIDDLE EAST AND AFRICA 267
- 11.6.1 SOUTH AFRICA 272
- 11.6.2 SAUDI ARABIA 277
- 11.6.3 U.A.E 282
- 11.6.4 ISRAEL 287
- 11.6.5 EGYPT 292
- 11.6.6 KUWAIT 297
- 11.6.7 REST OF MIDDLE EAST AND AFRICA 302
12 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 303
- 12.1 COMPANY SHARE ANALYSIS: GLOBAL 303
- 12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 304
- 12.3 COMPANY SHARE ANALYSIS: EUROPE 305
- 12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 306
13 SWOT ANALYSIS 307
14 GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 308
- 14.1 GILEAD SCIENCES INC. 308
- 14.1.1 COMPANY SNAPSHOT 308
- 14.1.2 REVENUE ANALYSIS 309
- 14.1.3 COMPANY SHARE ANALYSIS 309
- 14.1.4 PRODUCT PORTFOLIO 310
- 14.1.5 RECENT DEVELOPMENT 310
- 14.2 TERUMO CORPORATION 311
- 14.2.1 COMPANY SNAPSHOT 311
- 14.2.2 REVENUE ANALYSIS 311
- 14.2.3 COMPANY SHARE ANALYSIS 312
- 14.2.4 PRODUCT PORTFOLIO 312
- 14.2.5 RECENT DEVELOPMENT 312
- 14.3 GETINGE 313
- 14.3.1 COMPANY SNAPSHOT 313
- 14.3.2 REVENUE ANALYSIS 313
- 14.3.3 COMPANY SHARE ANALYSIS 314
- 14.3.4 PRODUCT PORTFOLIO 314
- 14.3.5 RECENT DEVELOPMENT 314
- 14.4 LIVANOVA PLC 315
- 14.4.1 COMPANY SNAPSHOT 315
- 14.4.2 REVENUE ANALYSIS 315
- 14.4.3 COMPANY SHARE ANALYSIS 316
- 14.4.4 PRODUCT PORTFOLIO 316
- 14.4.5 RECENT DEVELOPMENTS 316
- 14.5 MEDTRONIC 317
- 14.5.1 COMPANY SNAPSHOT 317
- 14.5.2 REVENUE ANALYSIS 317
- 14.5.3 COMPANY SHARE ANALYSIS 318
- 14.5.4 PRODUCT PORTFOLIO 318
- 14.5.5 RECENT DEVELOPMENTS 318
- 14.6 ARMSTRONG MEDICAL 319
- 14.6.1 COMPANY SNAPSHOT 319
- 14.6.2 PRODUCT PORTFOLIO 319
- 14.6.3 RECENT DEVELOPMENT 319
- 14.7 BESMED HEALTH BUSINESS CORP. 320
- 14.7.1 COMPANY SNAPSHOT 320
- 14.7.2 PRODUCT PORTFOLIO 320
- 14.7.3 RECENT DEVELOPMENTS 321
- 14.8 DRAGERWERK AG & CO. KGAA 322
- 14.8.1 COMPANY SNAPSHOT 322
- 14.8.2 REVENUE ANALYSIS 322
- 14.8.3 PRODUCT PORTFOLIO 323
- 14.8.4 RECENT DEVELOPMENTS 323
- 14.9 EUROSETS 324
- 14.9.1 COMPANY SNAPSHOT 324
- 14.9.2 PRODUCT PORTFOLIO 324
- 14.9.3 RECENT DEVELOPMENT 324
- 14.10 FISHER & PAYKEL HEALTHCARE LIMITED 325
- 14.10.1 COMPANY SNAPSHOT 325
- 14.10.2 REVENUE ANALYSIS 325
- 14.10.3 PRODUCT PORTFOLIO 326
- 14.10.4 RECENT DEVELOPMENTS 326
- 14.11 FRESENIUS SE & CO. KGAA. 327
- 14.11.1 COMPANY SNAPSHOT 327
- 14.11.2 REVENUE ANALYSIS 327
- 14.11.3 PRODUCT PORTFOLIO 328
- 14.11.4 RECENT DEVELOPMENT 328
- 14.12 HAMILTON MEDICAL 329
- 14.12.1 COMPANY SNAPSHOT 329
- 14.12.2 PRODUCT PORTFOLIO 329
- 14.12.3 RECENT DEVELOPMENT 329
- 14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD. 330
- 14.13.1 COMPANY SNAPSHOT 330
- 14.13.2 PRODUCT PORTFOLIO 330
- 14.13.3 RECENT DEVELOPMENT 330
- 14.14 NIPRO 331
- 14.14.1 COMPANY SNAPSHOT 331
- 14.14.2 REVENUE ANALYSIS 331
- 14.14.3 PRODUCT PORTFOLIO 332
- 14.14.4 RECENT DEVELOPMENT 332
- 14.15 PFIZER INC. 333
- 14.15.1 COMPANY SNAPSHOT 333
- 14.15.2 REVENUE ANALYSIS 333
- 14.15.3 PRODUCT PORTFOLIO 334
- 14.15.4 RECENT DEVELOPMENT 334
- 14.16 RESMED 335
- 14.16.1 COMPANY SNAPSHOT 335
- 14.16.2 REVENUE ANALYSIS 335
- 14.16.3 PRODUCT PORTFOLIO 336
- 14.16.4 RECENT DEVELOPMENT 336
- 14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 337
- 14.17.1 COMPANY SNAPSHOT 337
- 14.17.2 PRODUCT PORTFOLIO 337
- 14.17.3 RECENT DEVELOPMENT 337
15 QUESTIONNAIRE 338
16 RELATED REPORTS 341